Target: Galderma Group AG Research cutoff: 24 October 2026 Scope: Galderma’s political, communicative, operational, governance, ownership, and leadership footprint concerning Israel and Palestine.
Corporate Communications & Public Stance
Official corporate positioning
In its 2025 reporting, Galderma described itself as an international dermatology business organized around Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology, reporting USD 5.207 billion in 2025 sales and separating business performance into United States and International geographic categories.1
In its public sustainability disclosures, Galderma presents environmental, social, and governance considerations as part of its Integrated Dermatology Strategy and states commitments concerning employees, consumers, patients, healthcare professionals, and responsible corporate conduct.2
Galderma’s corporate governance publications describe ethical-business expectations applying to employees and business partners, including company codes addressing professional conduct and supplier behavior.3
Israel-Palestine statements
No public evidence identified of a directly attributable official Galderma Group AG statement expressly endorsing Israeli military operations, advocating Palestinian rights, supporting a particular party to the Israel-Palestine conflict, or addressing specific civilian casualties in Gaza.
Comparative public posture
During the 2025 reporting period, Galderma publicly quantified medical-education activities and published sustainability commitments, including information about employee engagement and healthcare-professional education.4
No public evidence identified from the directly reviewed sources of a comparably attributable Galderma Group AG public statement specifically addressing Palestinian civilian protection.
No public evidence identified sufficient to verify a complete comparative chronology of Galderma’s official statements on Ukraine, Russia, Black Lives Matter, COVID-19, and Gaza.
Market framing
Galderma’s March 2026 results announcement described regional performance through broad commercial reporting categories, including International markets and the United States, without presenting an Israel-specific political or geopolitical business objective.1
The company’s global-presence page identifies international operating locations and regional coverage, including a Middle East category, without separately identifying an Israeli manufacturing facility on that page.5
Operations in Occupied or Contested Territories
Geographic operations
Galderma publicly describes operations across approximately 90 countries and provides regional information about offices, research-and-development locations, and manufacturing facilities.5
Israel’s Ministry of Health operates a public registry through which users can check pharmaceutical products currently or historically registered in Israel, including registration status and product information.6
No public evidence identified in the directly verified source set of a specifically named Galderma-owned factory, office, registered subsidiary, warehouse, or contractual distribution location inside an Israeli settlement in the West Bank, occupied East Jerusalem, or the occupied Golan Heights.
Israeli commercial intermediaries
No public evidence identified sufficient to establish a directly verified current contractual relationship between Galderma and any specific Israeli distributor from the successfully retrieved primary documents.
No public evidence identified establishing that Galderma products were supplied under a named contract to the Israel Defense Forces, Israeli Ministry of Defense, or an Israeli settlement authority.
Legal and regulatory scrutiny
Israel’s Ministry of Health publishes information about pharmaceutical registration and describes the regulatory framework through which medicines receive authorization for marketing in Israel.7
No public evidence identified of a Galderma-specific court judgment, international enforcement decision, OECD National Contact Point determination, or documented regulatory sanction arising from commercial activity in occupied Palestinian territory.
No independently verified Galderma-specific inclusion in the UN OHCHR settlement-business database was established during this research.
Civil-society campaigns and boycott activity
A publicly accessible Brands2Boycott campaign page lists the Galderma-associated products Cetaphil and Sculptra among beauty products targeted by its consumer guidance, associating these products with Galderma’s historical investment consortium.8
The Palestinian BDS National Committee’s public divestment guidance describes broad targeting principles and priority categories for divestment campaigns, including Israeli corporations and activities associated with settlements.9
No public evidence identified in the directly reviewed BDS Movement material establishing Galderma as an expressly designated official priority boycott target.
No public evidence identified of a directly attributable official Galderma response to the Brands2Boycott listing.
Settlement-specific business links
No public evidence identified of Galderma sponsoring settlement development, operating a specifically identified settlement storefront, financing settlement construction, or holding a documented commercial contract with a settlement authority.
Internal Governance, Content & Retail Policies
Employee relations
Galderma’s sustainability publications describe employee dignity, privacy, rights, and organizational commitments concerning ethical treatment.2
Galderma identifies a formal governance framework under which employees and suppliers are expected to comply with corporate ethical standards.3
No public evidence identified of Galderma disciplining employees specifically for expressing support for Palestinians or Israelis.
No public evidence identified of Galderma terminating employees, restricting workplace political symbols, or initiating litigation against employee unions specifically because of Israel-Palestine-related expression.
No public evidence identified of an Israel-specific policy providing salary supplements to reservists or materially assisting military mobilization.
Platform and editorial policy
Galderma’s publicly disclosed operating categories concern dermatology products and professional medical services, and its 2025 performance reporting identifies no general-purpose social-media, public mapping, or consumer content-moderation platform as a principal product category.1
No public evidence identified of a Galderma-owned public platform suppressing Palestinian content, altering political maps, moderating Israel-Palestine commentary asymmetrically, or distributing applications to military devices.
Retail, sourcing, and labeling
Galderma’s public governance information identifies a Supplier Code and describes the company’s expectations for suppliers and business partners.3
No public evidence identified of a verified Galderma-specific settlement-origin labeling violation, deceptive origin declaration, settlement-manufactured ingredient arrangement, or related regulatory proceeding.
No public evidence identified of Galderma changing product-country labels, online regional classifications, or settlement designations following a request by Israeli authorities.
Shareholder and whistleblowing governance
Galderma’s governance structure includes a Finance and Audit Committee, a Compensation Committee, and a Strategy, ESG and Nomination Committee.10
No public evidence identified of a Galderma shareholder resolution about Israel-Palestine due diligence being suppressed, excluded, or litigated.
Brand Heritage & State Partnerships
Corporate heritage and commercial identity
Galderma traces its founding to 1981 and describes its continuing commercial purpose as advancing dermatology through scientific research, clinical development, pharmaceutical products, skincare, and injectable aesthetics.11
The company’s current marketing and corporate reporting identify dermatology and medical-science expertise as central to its commercial identity.11
No public evidence identified of Galderma commercially promoting Israeli military heritage, intelligence-service origins, defense-sector membership, or Israeli military affiliation as part of its brand identity.
Medical and academic partnerships
Galderma reported reaching more than 290,000 healthcare professionals during 2025 through education and medical-awareness programmes, including the Galderma Aesthetic Injector Network, and reported more than 10,000 GAIN training events globally.12
The company identifies international medical congresses and professional education programmes among its regular scientific-engagement activities.12
No public evidence identified of a verified Israel-specific military academic research agreement, Israeli defense-university partnership, or sponsorship of an Israeli government geopolitical public-relations campaign.
State honors and sponsorships
No public evidence identified of a Galderma executive receiving a state honor explicitly connected to support for Israeli military operations or settlement policy.
No public evidence identified of Galderma sponsoring a settlement celebration, Israeli military fundraising gala, or state-backed campaign advocating territorial annexation.
Lobbying, Advocacy, Financing & Logistics
Corporate lobbying and political advocacy
Galderma’s governance publications identify formal ethical and compliance structures, and its executive leadership includes a General Counsel and Chief Compliance Officer.3, 13
No public evidence identified of a Galderma corporate lobbying campaign concerning Israel-Palestine policy, anti-BDS legislation, military assistance, sanctions, or recognition of Palestinian statehood.
No public evidence identified of a Galderma corporate political-action committee making a specifically documented Israel-Palestine-related contribution.
Financial contributions
No public evidence identified of an attributable Galderma corporate contribution to the Israel Defense Forces, Friends of the Israel Defense Forces, Jewish National Fund/KKL, Lev Echad, Regavim, Im Tirtzu, settlement organizations, or Israeli military-welfare fundraising organizations.
No public evidence identified of Galderma providing a documented military-directed charitable matching programme or establishing a financial mechanism to fund Israeli reservists.
Crisis asset mobilization
Galderma’s 2025 reporting describes substantial international medical and dermatological education activities.12
No public evidence identified of Galderma providing free products, medical supplies, logistics, transportation, infrastructure, cloud services, accommodation, or other corporate assets to Israeli military operations during the Gaza conflict.
No public evidence identified establishing that a Galderma corporate humanitarian donation was specifically used to finance Israeli military or settlement operations.
Activities after major international legal developments
Following 19 July 2024 and November 2024, Galderma continued issuing corporate financial disclosures and expanded its relationship with L’Oréal through an announced 2025 share transaction and its subsequent 2026 governance changes.14, 15
No public evidence identified establishing that Galderma began, continued, or escalated any specifically documented military-support donation, settlement sponsorship, or Israel-Palestine lobbying campaign during either subsequent period.
Corporate Structure & Primary Mission
Legal structure and principal business
Galderma Group AG is a Swiss publicly traded company whose commercial activities encompass Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.1
Galderma’s investor-relations website publishes annual reports, financial statements, and investor disclosures covering the company’s reporting and governance arrangements.16
The company’s published historical and contemporary corporate descriptions identify dermatological treatment, skincare, pharmaceutical development, and related medical science as its business activities.11
Shareholder structure and changes
In December 2025, Galderma announced that L’Oréal intended to acquire a further 10% equity interest from a consortium associated with Sunshine SwissCo GmbH, EQT, Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd., bringing L’Oréal’s planned total holding to 20%.14
L’Oréal’s 2025 financial disclosure subsequently reported that the additional investment was completed on 10 February 2026 for approximately EUR 4.2 billion.17
L’Oréal’s December 2025 transaction announcement stated its intention to continue supporting Galderma’s strategy and independence while strengthening their existing scientific partnership.18
Galderma’s April 2026 AGM confirmed the election of Samuel du Retail and Delphine Viguier-Hovasse as non-independent board members representing L’Oréal.15
The April 2026 AGM also confirmed the continued tenure of Thomas Ebeling as Chair and Flemming Ørnskov as a member of the board.15
Historical investor changes
Galderma’s April 2025 AGM announcement identified Michael Bauer and Marcus Brennecke as directors during the preceding governance period.19
Galderma’s March 2026 AGM notice identified Michael Bauer and Marcus Brennecke as outgoing directors associated with the EQT-led consortium and described their anticipated replacement by L’Oréal representatives.20
Relationships with other corporate groups
L’Oréal’s 2025 Universal Registration Document identified Françoise Bettencourt Meyers and her family as holding 34.79% of L’Oréal’s share capital at 31 December 2025, with Nestlé holding 20.16%.21
These disclosed holdings represent equity interests in L’Oréal, while L’Oréal’s directly disclosed equity holding in Galderma was 20% following the February 2026 transaction.17, 21
An Ethical Consumer company profile describes L’Oréal’s Israeli subsidiary, L’Oréal Israel Ltd., as part of L’Oréal’s direct corporate operations in Israel.22
No public evidence identified establishing that L’Oréal Israel Ltd. is a Galderma subsidiary, that its Israeli activities are governed by Galderma, or that its specific operations have been transferred to Galderma.
Foundational mandate
Galderma’s public corporate mission and business descriptions concern dermatological products, health, medical innovation, and related commercial services.11
No public evidence identified of Galderma having a state-owned golden share, a founding legal mandate to advance Israeli geopolitical policy, or a corporate charter requiring support for Israeli state or military operations.
Executive & Leadership Footprint
Current leadership
Galderma’s published governance page identifies Thomas Ebeling as Chair, Sherilyn McCoy as Vice-Chair, and Flemming Ørnskov as a board member and CEO.10
The board composition published following the April 2026 AGM includes Daniel Browne, Maria Teresa Hilado, Harry Kirsch, Karen Ling, Roberto Marques, Samuel du Retail, and Delphine Viguier-Hovasse.15
Galderma’s executive leadership page identifies Flemming Ørnskov as CEO, Luigi La Corte as CFO, Adrian Murphy as Global Head of Operations, and Nakisa Serry as General Counsel and Chief Compliance Officer.13
Shareholder-appointed governance
Galderma’s December 2025 transaction announcement identified L’Oréal’s increased investment as the basis for proposing two board members associated with the shareholder.14
The March 2026 AGM notice identified Delphine Viguier-Hovasse as L’Oréal’s Chief Innovation & Prospective Officer and Samuel du Retail as L’Oréal’s Managing Director of Artificial Intelligence, Data and Shared Services.20
L’Oréal’s December 2025 announcement identified Nicolas Hieronimus as the company’s CEO and quoted his support for the enlarged Galderma investment as part of L’Oréal’s commercial interests in the aesthetics market.18
Personal philanthropy and military financing
No public evidence identified of an attributable donation by Thomas Ebeling, Flemming Ørnskov, Sherilyn McCoy, Nicolas Hieronimus, or the other identified current Galderma directors to FIDF, the IDF, JNF/KKL, an Israeli settlement organization, or an Israeli military-welfare fund.
No public evidence identified establishing that a family foundation controlled by a named Galderma director financed Israeli military activities or settlement infrastructure.
Public advocacy and political statements
No public evidence identified of a verified public statement by the identified current Galderma leadership explicitly endorsing Israeli military action in Gaza, advocating Israeli settlement expansion, calling for the suppression of Palestinian political activity, or promoting anti-BDS legislation.
No public evidence identified of a documented Galderma executive public appearance at an Israeli military fundraising ceremony or settlement endorsement event.
Board affiliations and potential external relationships
Galderma identifies current directors and describes its board committee structure through its official governance disclosures.10
No public evidence identified of a current Galderma director holding a verified leadership position in AIPAC, FIDF, Regavim, Im Tirtzu, or an Israeli settlement advocacy organization.
No public evidence identified establishing a directly attributable investment by a named Galderma executive or their controlled foundation in an Israeli military-surveillance or defense company.
Historical and ongoing relationship boundaries
Michael Bauer and Marcus Brennecke were members of Galderma’s 2025 board, but Galderma’s 2026 AGM announcements document their replacement following L’Oréal’s increased shareholding.19, 20
Samuel du Retail and Delphine Viguier-Hovasse were elected to Galderma’s board on 22 April 2026 and are identified by Galderma as representatives of L’Oréal.15
Footnotes
-
Galderma, “Galderma delivers record 2025 results,” 5 March 2026. https://www.galderma.com/news/galderma-delivers-record-2025-results ↩ ↩2 ↩3 ↩4
-
Galderma, “Sustainability,” accessed 24 October 2026. https://www.galderma.com/sustainability ↩ ↩2
-
Galderma, “Governance Oversight,” accessed 24 October 2026. https://www.galderma.com/governance-oversight ↩ ↩2 ↩3 ↩4
-
Galderma, “Annual Report 2025,” 2026. https://www.galderma.com/annual-report-2025 ↩
-
Galderma, “Global Presence,” accessed 24 October 2026. https://www.galderma.com/global-presence ↩ ↩2
-
Israel Ministry of Health, “Search for information on the Israeli Drug Registry,” accessed 24 October 2026. https://web.archive.org/web/20250701164111/https://www.gov.il/en/service/israeli-drug-index (archived copy of www.gov.il/en/service/israeli-drug-index, Wayback 2025-07-01; live page unreachable from the verifier) ↩
-
Israel Ministry of Health, “Search for information on the Israeli Drug Registry,” accessed 24 October 2026. https://web.archive.org/web/20250701164111/https://www.gov.il/en/service/israeli-drug-index (archived copy of www.gov.il/en/service/israeli-drug-index, Wayback 2025-07-01; live page unreachable from the verifier) ↩
-
Brands2Boycott, “Beauty,” campaign product list, accessed 24 October 2026. https://brands2boycott.org/boycottlist/beauty/ ↩
-
BDS Movement, “Get Involved - Divestment,” accessed 24 October 2026. https://www.bdsmovement.net/Get-involved-divestment ↩
-
Galderma, “Governance,” accessed 24 October 2026. https://www.galderma.com/governance ↩ ↩2 ↩3
-
Galderma, “Galderma welcomes increased equity investment from L’Oréal,” 8 December 2025. https://www.galderma.com/news/galderma-welcomes-increased-equity-investment-loreal ↩ ↩2 ↩3 ↩4
-
Galderma, “For Healthcare Professionals and Customers,” accessed 24 October 2026. https://www.galderma.com/healthcare-professionals-and-customers ↩ ↩2 ↩3
-
Galderma, “Executive Committee,” accessed 24 October 2026. https://www.galderma.com/executive-committee ↩ ↩2
-
Galderma, “Galderma welcomes increased equity investment from L’Oréal,” 8 December 2025. https://www.galderma.com/news/galderma-welcomes-increased-equity-investment-loreal ↩ ↩2 ↩3
-
Galderma, “Galderma shareholders approve all Annual General Meeting proposals,” 22 April 2026. https://www.galderma.com/news/galderma-annual-general-meeting-2026 ↩ ↩2 ↩3 ↩4 ↩5
-
Galderma Investor Relations, “Financial Reports,” accessed 24 October 2026. https://web.archive.org/web/20260420180007/https://investors.galderma.com/financial-reports (archived copy of investors.galderma.com/financial-reports, Wayback 2026-04-20; live page unreachable from the verifier) ↩
-
L’Oréal, “2025 Universal Registration Document,” parent-company financial statements, page 373, published 2026. https://www.loreal-finance.com/eng/2025-universal-registration-document/en/article/373/ ↩ ↩2
-
L’Oréal Groupe, “L’Oréal Groupe to reinforce its strategic investment in Galderma,” 8 December 2025. https://www.loreal.com/en/press-release/group/loreal-to-reinforce-its-investment-in-galderma/ ↩ ↩2
-
Galderma, “Galderma shareholders approve all Annual General Meeting proposals,” 23 April 2025. https://www.galderma.com/news/galderma-shareholders-approve-all-annual-general-meeting-proposals ↩ ↩2
-
Galderma, “Galderma publishes invitation and agenda for its 2026 Annual General Meeting,” 20 March 2026. https://www.galderma.com/news/galderma-publishes-invitation-and-agenda-its-2026-annual-general-meeting ↩ ↩2 ↩3
-
L’Oréal, “2025 Universal Registration Document,” Ownership Structure, page 395, published 2026. https://www.loreal-finance.com/eng/2025-universal-registration-document/en/article/395/ ↩ ↩2
-
Ethical Consumer, “How ethical is L’Oréal S.A?,” 2026. https://www.ethicalconsumer.org/company-profile/loreal-sa ↩